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Background: Pituitary adenoma may present with neuro-ophthalmic manifestations and, typically, rapid tumor
expansion is the result of apoplexy. Herein, we present the first case of an isolated sixth cranial nerve palsy as
initial feature of a rapidly expanding ACTH positive silent tumor without apoplexy.
Case Presentation: A 44 year old female with a history of sarcoidosis presented with an isolated sixth cranial
nerve palsy as the initial clinical feature of a rapidly expanding ACTH positive silent pituitary adenoma. The patient
underwent emergent transsphenoidal hypophysectomy for this rapidly progressive tumor and subsequently
regained complete vision and ocular motility. Despite tumor extension into the cavernous sinus, the other cranial
nerves were spared during the initial presentation.
Conclusions: This case illustrates the need to consider a rapidly growing pituitary tumor as a possibility when
presented with a rapidly progressive ophthalmoplegia.
Background
Pituitary adenoma, the most common cause of sellar
masses after the third decade of life, may present with
neuro-ophthalmic manifestations. Visual impairment is
the most common presenting symptom in patients with
a non-secreting adenoma as a result of chiasmal com-
pression [1-3]. Less commonly, lateral extension of the
adenoma into the cavernous sinus will often cause com-
pression of the third cranial nerve [4], resulting in diplo-
pia. These tumors typically grow slowly unless pituitary
apoplexy - defined as acute hemorrhagic infarction of
the pituitary adenoma causing increased intra-sellar
pressure often resulting in acute onset of headache, nau-
sea, vomiting, ophthalmoplegia, visual loss, and even
hypopituitarism - is present [5]. Herein we present the
first case of an isolated sixth cranial nerve palsy as the
presenting clinical feature of a rapidly expanding ACTH
positive silent tumor without apoplexy.
Case Presentation
A 44-year-old female with past medical history signifi-
cant for sarcoidosis, not currently receiving treatment,
and hypertension presented to the clinic with a chief
complaint of vague headaches and horizontal diplopia
that worsened with left gaze of one days’ duration.
Neuro-ophthalmologic exam revealed an isolated,
incomplete, left cranial nerve six palsy. Visual acuity was
20/20 bilaterally, Humphrey visual field testing with
24-2 testing strategy was full bilaterally, and dilated fundus
examination revealed the absence of papilledema and a
normal retinal periphery. There was no clinical evidence
of either myasthenia gravis or thyroid ophthalmopathy.
An MRI of the orbits and brain (Figures 1, 2) revealed
a 1.5 × 1.9 × 1.4 cm mass within the sella, displacing
the pituitary gland and infundibulum towards the right
and impinging on the left cavernous sinus. The mass
extended into the suprasellar cistern, but did not com-
press the optic chiasm. There were intra-lesional areas
of increased signal intensity on T1 and T2 weighted
sequences that likely represented minimal hemorrhage,
insufficient to qualify as apoplexy. There was no evi-
dence of intracranial sarcoidosis.
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surgical service for preoperative studies and scheduled
for urgent transsphenoidal hypophysectomy. Preopera-
tive and systemic work up was initiated, inclusive of
complete blood count, metabolic profile, coagulation
studies, sedimentation rate, thyroid function tests, acet-
ylcholine receptor antibodies both binding and blocking,
& angiotensin converting enzyme. All tests were within
normal limits aside from an elevated ACE, which was
unchanged from previous examination. Review of his-
tory and physical exam revealed no clinical evidence of
hypercortisolemia, hyperprolactinemia, or menstrual
dysfunction. Evaluation of the pituitary hormone status
of tumor, inclusive of ACTH, cortisol, prolactin, IGF-1,
LH, and FSH, was scheduled but could not be com-
pleted due to rapid clinical deterioration.
The patient remained stable over the next 36 hours, at
which point she developed a left-sided, severe, retro-
orbital headache. Over the next four hours the patient
developed acute left sided ptosis and proptosis with
complete ophthalmoplegia and decreased visual acuity,
findings consistent with complete cavernous sinus invol-
vement. An emergent head CT was then obtained which
demonstrated an enlarging mass in the sella without evi-
dence of intra- or extra-lesional hemorrhage. Final
dimensions of the tumor on this non-contrast head CT
were 1.5 × 1.3 × 2.4 cm, overall a significant increase in
size from the measured dimensions of 1.5 × 1.9 × 1.4 cm
found on initial MRI especially given that MRI has been
shown to provide better evaluation of pituitary macroa-
denomas [6,7].
The patient underwent emergent transsphenoidal
hypophysectomy for this rapidly progressive tumor.
Intraoperatively, the tumor was found to have clinical
extension into the cavernous sinus. Pathologic examina-
tion of the mass (Figures 3, 4, 5) demonstrated a 1.5 ×
1.0 × 0.3 cm pituitary adenoma positive for ACTH
immunostain. No frank hemorrhage or necrosis was
noted. Post-operatively the patient was placed on intra-
venous Decadron, which was tapered over 10 days. She
immediately regained visual acuity and the VIth nerve
palsy resolved over the subsequent two months. Post-
operative scans, however, continued to demonstrate
tumor presence and growth and the patient underwent
a second resection one month following the initial sur-
gery, followed by stereotactic Gamma knife radiation
seven months later. Now, 5 months post her last proce-
dure, she remains free of symptoms with complete ocu-
lar motility, 20/20 visual acuity, and full visual fields.
There have been no changes in her reported symptoms
of sarcoidosis.
Conclusions
The cavernous sinus contains the carotid artery as well
as the oculomotor, trochlear, ophthalmic and maxillary
divisions of the trigeminal, and abducens nerves. Extrao-
cular palsy generally indicates compression of the caver-
nous sinus wall or direct extension of the pituitary
adenoma into the cavernous sinus [3,8]. The incidence
of ocular palsy occurring with pituitary tumors has been
reported to be between 4.6 and 32% [9-12]. Most com-
monly affected is the oculomotor nerve; rarely is the
abducens nerve involved [3,13]. A retrospective review
of 64 patients hospitalized with pituitary adenoma [9]
found that a defect in ocular movement was present in
14% of patients, with oculomotor nerve involvement in
78% of cases. The sixth cranial nerve runs lateral to the
Figure 1 T1 post-contrast axial MRI shows a tumor within the
sella displacing the pituitary gland and infundibulum.
Figure 2 T1 post-contrast coronal MRI shows a mass
impressing on the left cavernous sinus.
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and first and second divisions of the fifth cranial nerves
which run superior to inferior within the lateral dural
border of the cavernous sinus. It is therefore more often
spared because of its more sheltered position within the
sinus [14]. Our patient is unusual in that initially the
sixth cranial nerve paresis was in isolation.
Despite the patients past medical history being posi-
tive for sarcoidosis, there was no evidence of neurosar-
coidosis in this case. Overall, 25-60% of patients with
systemic sarcoidosis will develop ocular symptoms,
while 5% will develop neurosarcoidosis. Cranial nerve
neuropathies are the most frequent neurological mani-
festation; cranial nerves II, III, IV, V, VI, and VII may
be affected individually or in combination [15-17].
The rapid expansion of the tumor secondary to tumor
growth and not apoplexy, as evidenced by the lack of
acute hemorrhage observed on imaging and subse-
quently on pathological examination, in this ACTH
positive silent tumor is highly unusual. In a series of
non-operated patients, the mean increase in tumor dia-
meter was 0.6 mm per year [5]. Furthermore, in a five
year period only half of macroadenomas demonstrated
any growth [18]. There has been evidence to suggest
that silent corticotroph adenomas, which are histologi-
cally and immunocytologically distinct from clinically
non-functioning adenomas, have a higher frequency of
aggressiveness and recurrence. The most common find-
ing associated with these silent corticotroph tumors is
rapidly progressive visual field defects. A study of 23
cases of silent pituitary corticotroph adenomas [20]
found that these tumors were more likely to be macroa-
denomas, undergo hemorrhagic infarction, present with
symptoms due to mass effect, and have a high rate of
recurrence. However, increased rates of aggressive beha-
vior in ACTH-positive tumors could not be demon-
strated in other studies [18-21]. This case suggests that
pituitary neoplasms that demonstrate rapid expansion as
a result of tumor growth may require different treat-
ment paradigms than typically behaving lesions.
Acknowledgements
Statement of Written, Informed Consent, 10/27/10: written informed consent
was obtained from the patient for publication of this case report and any
accompanying images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
Author details
1Department of Ophthalmology, Mount Sinai School of Medicine, New York,
NY, USA.
2Department of Ophthalmology, Maimonides Medical Center,
Brooklyn, New York, USA.
3Mount Sinai School of Medicine, New York, NY,
USA.
4Department of Pathology, Division of Neuropathology, New York
University, New York, NY, USA.
5Department of Neurosurgery, New York
University Langone Medical Center, New York, NY, USA.
Figure 3 Histopathology revealed pituitary adenoma
composed of monomorphous cells with amphophilic
cytoplasm (hematoxylin and eosin, X20).
Figure 4 Reticulin special stain demonstrates loss of the usual
acinar pattern supporting the diagnosis of pituitary adenoma
(hematoxylin and eosin, X20).
Figure 5 The tumor is diffusely positive for ACTH immunostain
(hematoxylin and eosin, X20).
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